SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2003-02-0440. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-02-0440v1 102/5/1595    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lemoli, R. M. Articles by Baccarani, M. Search for Related Content PubMed PubMed Citation Articles by Lemoli, R. M. Articles by Baccarani, M. Related Collections Neoplasia Phagocytes Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2003, Vol. 102, No. 5, pp. 1595-1600 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Autologous transplantation of granulocyte colony-stimulating factor–primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization Roberto M. Lemoli, Antonio de Vivo, Daniela Damiani, Alessandro Isidori, Monica Tani, Alessandro Bonini, Claudia Cellini, Antonio Curti, Luigi Gugliotta, Giuseppe Visani, Renato Fanin, and Michele Baccarani From the Institute of Hematology and Medical Oncology "L.&A. Seràgnoli," University of Bologna, Italy; the Hematology Service "S. Maria Nuova" Hospital, Reggio Emilia, Italy; the Hematology Service "S. Salvatore" Hospital, Pesaro, Italy; and the Chair of Hematology, University Hospital, Udine, Italy. We assessed the hematopoietic recovery and transplantation-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF)–primed bone marrow (BM). Studied were 86 heavily pretreated consecutive patients with acute leukemia (n = 21), refractory/relapsed non-Hodgkin lymphoma (n = 41) and Hodgkin disease (n = 17), and multiple myeloma (n = 7). There were 78 patients who showed insufficient mobilization of CD34+ cells (< 10 cells/µL), whereas 8 patients collected less than 1 x 106 CD34+ cells/kg. BM was primed in vivo for 3 days with 15 to 16 µg/kg of subcutaneous G-CSF. Median numbers of nucleated cells, colony-forming unit cells (CFU-Cs), and CD34+ cells per kilogram harvested were 3.5 x 108, 3.72 x 104, and 0.82 x 106, respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count higher than 0.5 x 109/L and an unsupported platelet count higher than 20 and 50 x 109/L were 13 (range, 8-24), 15 (range, 12-75), and 22 (range, 12-180) days, respectively, for lymphoma/myeloma patients and 23 (range, 13-53), 52 (range, 40-120), and 90 (range, 46-207) days, respectively, for leukemia patients. Median times to hospital discharge after transplantation were 17 (range, 12-40) and 27 (range, 14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6%, whereas 15 patients died of disease. G-CSF–primed BM induces effective multilineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. M. Lemoli and A. D'Addio Hematopoietic stem cell mobilization Haematologica, March 1, 2008; 93(3): 321 - 324. [Full Text] [PDF] S. Fukuda, H. Bian, A. G. King, and L. M. Pelus The chemokine GRO{beta} mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment Blood, August 1, 2007; 110(3): 860 - 869. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020